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Abstract 
Objectives 
The objectives of this study were to assess owner perceptions of their cat’s quality of life 
during treatment for lymphoma with a doxorubicin-containing multi-agent chemotherapy 
protocol, whether various health-related parameters correlated with quality of life scores, 
and to assess owner satisfaction with the protocol.   
Methods  
A postal questionnaire was sent to the owners of 33 treated cats.  Owners retrospectively 
assessed their cat’s quality of life using a Likert scale (1-10), before lymphoma was 
diagnosed, at diagnosis and during chemotherapy.  Owners assigned scores to various 
health-related parameters previously reported to affect quality of life at the 3 time points, 
and correlations with quality of life scores were sought.  Owners were asked to rate the 
importance of these health-related parameters.  Satisfaction with the protocol was 
investigated. 
Results  
Twenty questionnaires were completed (61% response rate). The median quality of life 
score before diagnosis (10, range 5-10) was higher than at diagnosis (3, range 1-9) (p<0.05). 
The median quality of life score during chemotherapy (7, range 3-9) was lower than before 
diagnosis (p<0.05) and higher than at diagnosis, but not statistically significant.  Quality of 
life scores did not correlate with individual health-related parameter scores consistently, 
however, quality of life scores did correlate with appetite scores during chemotherapy. 
Appetite, vomiting and diarrhoea were parameters perceived as important in affecting 
quality of life.  Most owners (75%) were happy they had treated their cat.  
Conclusions and relevance  
The quality of life scores observed were comparable to a previous study using 
cyclophosphamide, vincristine and prednisolone, employing the same scoring system.  
Although quality of life scores during chemotherapy were not significantly improved at 
diagnosis, owner satisfaction with the protocol was high   
The factors perceived by owners to determine quality of life in their pets may be different to 
those previously conjectured, but appetite during chemotherapy remains important.   
Introduction 
Lymphoma is the most common malignancy in cats, accounting for 30% of all feline tumours 
and 90% of haematopoietic tumours.1-3 Chemotherapy is the treatment of choice for most 
cases of feline lymphoma,4 however some owners decline treatment due to concerns 
regarding a decrease in quality of life (QOL), potential suffering, and lack of cure.5, 6 Pet 
owners may perceive QOL as more important than longevity,6, 7 and this should be taken 
into account when establishing treatment objectives.8  
 
There is no globally accepted definition of quality of life.9, 10 It is generally considered to be a 
multifaceted concept involving the subjective evaluation of factors that contribute to overall 
well-being.11 In human cancer patients, the need to assess the impact of cancer and its 
treatment on a patient’s quality of life is well recognised.12 Patient-based measures such as 
appetite and mood have been shown to be significant independent predictors of survival.13-
15 This evidence from human medicine supports the need for regularly assessing quality of 
life in veterinary cancer patients.  
 
In people, it is well reported that there is a discrepancy between an individual’s opinion of 
their own quality of life and that of a proxy informant.16-18 This is potentially a source of 
error in veterinary medicine, however proxy assessing is currently the best means for 
evaluating quality of life in animals,9 and the owner is considered a better proxy informant 
than the attending veterinarian.19 Previous studies suggest that a simple questionnaire can 
be useful in assessing health-related quality of life of dogs and cats with cancer. 20-23, 24-26 
Questionnaire design should employ objective measures to help standardize responses and 
increase the reliability of proxy QOL assessments.9 
 It has been suggested that the QOL of cats receiving a cyclophosphamide, vincristine and 
prednisolone (COP) protocol for treatment of lymphoma might be superior to that of cats 
receiving a doxorubicin-containing protocol (CHOP-type protocol).24 Incorporation of 
doxorubicin might introduce additional adverse effects, such as myelosuppression, nausea, 
vomiting, anorexia and renal toxicity, which could all affect QOL. 27-34 However, to the 
authors’ knowledge there have been no previous QOL assessments in cats receiving a 
doxorubicin-containing chemotherapy protocol for lymphoma. 
 
The purpose of this study was to assess owner perceptions of their cat’s QOL during 
treatment of lymphoma with a doxorubicin-containing multi-agent chemotherapy protocol, 
and to draw comparisons with a previous study using COP chemotherapy.24 Associations 
between various health-related parameters previously reported to reflect quality of life (e.g. 
appetite) and the owners’ assessment of their cat’s QOL were explored. The null hypothesis 
was that there would be no difference in QOL, as perceived by owners of cats with 
lymphoma at three time points: Before diagnosis of lymphoma, at time of diagnosis and 
during the doxorubicin-containing chemotherapy protocol; and that there would be no 
correlation between previously reported health-related parameters perceived to affect QOL 
and QOL scores.  Owner satisfaction with the protocol was assessed.   
Materials and methods 
The medical records database of the Queen Mother Hospital for Animals, Royal Veterinary 
College, University of London was searched for cats diagnosed with lymphoma between 
2001-2008. Cats met the inclusion criteria if a cytological or histological diagnosis of 
lymphoma was made and the cats received ≥ 4 weeks of a modified University of Wisconsin 
Madison doxorubicin-containing chemotherapy protocol (see Supplementary material). Cats 
pre-treated with corticosteroids or other chemotherapeutic agents were excluded. 
Information regarding age, sex, breed, duration of clinical signs prior to treatment and 
anatomical location of lymphoma was collected.  A postal questionnaire was designed and 
pretested for readability and ambiguity.  The Royal Veterinary College ethics committee 
approved the study. 
 
The questionnaire (see Supplementary material) was sent to owners of all eligible cats, a 
maximum of 9 years after the initial diagnosis. The questionnaire included questions about 
their perception of their cat’s quality of life at three time points: Before diagnosis of 
lymphoma, at diagnosis and during chemotherapy. The questions were structured using a 
10-point Likert scale where 1 = quality of life could not be worse and 10 = quality of life 
could not be better. The owners were asked to score various health-related parameters that 
might affect their cat’s quality of life:  Appetite, body weight, general activity level, 
playfulness, sleeping, grooming activity, vomiting, and diarrhoea; at the same three time 
points on similar ten-point Likert scales. They were also asked if fur and whisker loss 
occurred during chemotherapy.  The owner’s perception of the importance of the different 
health-related parameters on their cat’s quality of life was interrogated.  The owners were 
asked how they felt towards chemotherapy for pets before their cat was diagnosed with 
cancer, how they felt about treating their own cat with chemotherapy and how they felt 
about chemotherapy for pets in general, after their experience of having treated their cat. 
 
Data analysis was performed using Microsoft® Excel 2002 and R software (R v 3.1.2, R 
Foundation for Statistical Computing, Vienna, Austria). Non-parametric continuous data 
were broken into quartiles and summarised as median and range. Categorical variables 
were summarised as counts and percentages. Cat variables were age, sex, breed, anatomical 
location of the lymphoma, duration of clinical signs, plus owner feelings about 
chemotherapy. They were assessed for effect on quality of life scores using the Kruskal-
Wallis test. Friedman’s ANOVA was used to test the effects of owner’s rating of their cats’ 
characteristics on quality of life scores before diagnosis of lymphoma, at diagnosis and 
during chemotherapy. Follow up post hoc tests were performed with the friedmanmc() 
function from the pgirmess package in R. The association between quality of life scores and 
scores for factors affecting quality of life were determined using Spearman’s Rank Order 
Correlation test. The level of significance was set at p < 0.05.   
Results 
The questionnaire was found to be un-ambiguous and readable in the pretesting stage. 
Thirty three cats met the inclusion criteria and 20 owners completed the questionnaire, 
giving a response rate of 61%.  
 
The median age at diagnosis was 5 years (range 13-168 months). Eleven cats (55%) were 
neutered males, 2 cats (10%) were entire males and 7 (35%) were entire females. Breeds 
represented were domestic (n=15), and one case each of Burmese, Siamese, Exotic Short 
Hair, British Short Hair and Abyssinian. Five cats (25%) were diagnosed with alimentary 
lymphoma, 8 cats (40%) were diagnosed with extra-nodal lymphoma (renal (n=3) and one 
each for spinal, nasopharynx, pericardium/pleural, laryngeal and tracheal), 5 cats (25%) 
were diagnosed with mediastinal lymphoma and 2 cats (10%) were diagnosed with multi-
centric lymphoma. The median duration of clinical signs before treatment was instigated 
was 20.5 days (range 1-28 days).  All cats received doxorubicin.  
 
Before their cats were diagnosed with lymphoma, 30% (n=6) owners supported the use of 
chemotherapy in pets, 25% (n=5) had no strong feelings either way about chemotherapy 
and 45% (n=9) had not thought about chemotherapy for pets. As expected, none of these 
owners objected to the use of chemotherapy in pets prior to treatment. These feelings did 
not have a significant effect on the QOL scores before treatment. 
 
A total of 75% (n=15) of owners were happy they chose to treat their cat, 15% (n= 3) were 
not sure how they felt and 10% (n=2) regretted treating their cat.  Having treated a cat with 
lymphoma with the current protocol, 80% (n=16) of owners supported the use of 
chemotherapy in pets, 15% (n=3) had no strong feelings about chemotherapy and 5% (n=1) 
objected to the use of chemotherapy in pets.  
 
The quality of life scores are presented in Figure 1. The scores were significantly lower at 
diagnosis than before lymphoma was diagnosed. The quality of life scores during 
chemotherapy were significantly lower than the quality of life scores before lymphoma was 
diagnosed and were higher during chemotherapy than at diagnosis, although this difference 
was not statistically significant.  
  
Appetite, body weight, general activity, playfulness and grooming scores were significantly 
lower at diagnosis compared to the time before lymphoma was diagnosed. Sleeping and 
vomiting scores were significantly higher at diagnosis compared to before lymphoma being 
diagnosed. For these a higher score reflected an increase in sleeping and vomiting. None of 
the health-related parameter scores changed significantly at diagnosis compared to those 
during chemotherapy.  
 
Correlations between quality of life scores and the health-related factors were assessed 
using Spearman’s rank test. Before diagnosis, there was no correlation between any of the 
parameter scores analysed and the quality of life scores. At diagnosis, body weight, general 
activity level, playfulness and grooming scores were significantly correlated with quality of 
life scores and during chemotherapy, appetite scores were significantly correlated with 
quality of life scores during (See Table 1).  
 
Owners were asked to rate the importance of the different parameters in relation to their 
effect on QOL (See Figure 2), A total of 65% of owners perceived that appetite was very 
important in affecting their cat's quality of life, whilst 75% and 70% of owners perceived 
that vomiting or diarrhoea were very important respectively. 
 
The investigators did not interrogate specifically whether hair loss or whisker loss were 
related to QOL scores.  A relatively high percentage of owners classed these factors as “not 
important” in relation to QOL compared to the other health-related factors (See Figure 2).  It 
is interesting to note, however, that twenty five percent of cats (n=5) experienced fur loss 
and 45% (n=9) experienced whisker loss during treatment.   
 
The age at diagnosis, sex, breed, anatomical location of lymphoma and median duration of 
clinical signs before treatment was instigated did not significantly affect the quality of life 
scores given (data not shown).   
Discussion 
To the authors’ knowledge this is the first study assessing the quality of life of cats with 
lymphoma treated with a doxorubicin-containing (modified University of Madison-
Wisconsin) protocol. The questionnaire response rate of 61% was high showing that the 
owners of these cats were, as expected, highly motivated. The pilot study demonstrated 
that the questionnaire was easily readable and the results of the survey reaffirm that a 
questionnaire-based method is an appropriate way to assess owner perceptions. 
 
In this study, whilst the chemotherapy did not significantly improve perceived quality of life, 
it did not reduce it from the score given at time of diagnosis.  We might have hoped that 
QOL would have improved significantly with chemotherapy treatment, particularly if 
treatment was effective. The quality of life scores in this study were however comparable to 
a previous study assessing a cyclophosphamide, vincristine and prednisolone protocol that 
used a similar 10-point Likert scale scoring system,24 suggesting that the current 
doxorubicin-containing protocol was as well tolerated as a COP protocol in cats. The fact 
that 80% of the owners in this study supported the use of chemotherapy in pets, having 
treated a cat with the current protocol, endorses its use. These results can be used to guide 
owner expectations for cats receiving a doxorubicin-containing chemotherapy protocol. The 
use of doxorubicin did not appear to adversely affect QOL, however its incorporation into 
the treatment protocol potentially carries extra expense and risks (e.g. tissue damage if 
extravasated).  Thus a randomized prospective clinical trial should ideally be performed to 
compare this protocol versus COP in terms of efficacy and QOL, to see if doxorubicin 
provides added clinical benefit.  
 
Various health-related parameters, considered to affect quality of life in previously 
published studies, were assessed to investigate their effect on the QOL of cats’ scores in this 
study. Quality of life scores did not correlate with individual health-related parameter scores 
consistently at the different time points.  Most owners perceived that appetite, vomiting 
and diarrhoea were very important factors in relation to QOL and yet only appetite scores 
during chemotherapy and body weight, activity level, playfulness and grooming at diagnosis 
correlated with quality of life scores. These findings suggest that there are other factors in 
play when we ask an owner to evaluate their cat’s quality of life, besides those conjectured 
by previous authors of quality of life studies in pets; and that the measurement of quality of 
life is complicated and multi-factorial. The discordance between what owners in this study 
thought was important and which factors actually correlated with quality of life scores 
suggests that perhaps we are not assessing quality of life in the correct way, and leaves us 
with the question of whether we can at present reliably assess the quality of life of pets. 
 
Sixty five per cent of owners in the current study considered that appetite was very 
important in QOL and appetite did correlate with QOL during chemotherapy.   It is 
noteworthy that, in a recent study of cats with lymphoma, 75% of cats treated with a similar 
protocol (containing L’asparaginase, vincristine, cyclophosphamide, doxorubicin and 
prednisolone) suffered anorexia.31 Whilst appetite is important nutritionally, owners are 
also using it as a marker of quality of life and thus may discontinue treatment or have 
negative feelings around chemotherapy if appetite is not a treated as a priority. Low body 
condition score at diagnosis of lymphoma is a negative prognostic indicator, further 
supporting the need for adequate caloric intake.34, 35 Instituting good prophylactic care, such 
as anti-emetics, gastric protectants, appetite stimulants (and in some cases temporary 
feeding tubes) could be effective measures in improving perceived and actual patient well-
being. 
 
Data from human patients with dementia has shown that proxy scores are often very 
different to the individual’s own scores.18, 36 Discrepancies have been shown to be 
associated with caregiver-related factors such as psychological burden, depression and 
health.17, 18, 37. In children with asthma it has been shown that negative caregiver affect i.e. 
the negative emotions the caregiver feels, is a primary determinant of how the caregiver 
scores their care-receiver’s quality of life,38 and we know from human medicine that 
caregiver perceptions of their own personal situation change their perception of their 
proxy’s quality of life.39 Therefore owners’ state of mind may play a role in proxy informing.   
 
The primary limitation of this study was that there were low numbers of owners completing 
the questionnaire. It is possible that the increase in quality of life scores during 
chemotherapy would have been statistically significant if a larger number of cats had been 
studied. In addition, the study was retrospective and therefore not all data was available for 
all cases, including response to chemotherapy, Feline leukaemia virus/Feline 
immunodeficiency virus status, median survival time, and further cytological or 
histopathological information. Remission status was not consistently assessed in this study 
and the disease status might have played a role in affecting the QOL scores. The 
questionnaire was also sent to owners up to 9 years after the initial diagnosis, which is 
another major limitation. The authors attempted to address non-respondent bias by having 
both positive and negative descriptors in the questionnaire however there is unlikely to 
remove it entirely. Although the questionnaire has not been validated, it was pretested for 
readability and ambiguity and to date there are no validated questionnaires designed to 
measure quality of life in pets with cancer.11 A larger, prospective study, directly comparing 
the quality of life of feline lymphoma patients receiving different protocols, with uniform 
staging and follow up procedures, concurrently assessing owner demographics and owner 
quality of life, would be an ideal model to explore, following on from this study. As it is still 
unclear what parameters owners and veterinarians use to evaluate the quality of life of cats, 
it would seem prudent to investigate this further.  
 
As previously alluded to, there is no universally accepted definition of quality of life and 
there is also no universally accepted measure of quality of life of cats. The authors believe it 
may be possible to objectively measure quality of life however results from this study 
suggest this area needs further work. This does not mean the concept of quality of life 
shouldn’t be discussed with owners but that they should be asked what the phrase ‘quality 
of life’ means to them, as different owners may not use the factors we conjecture, to 
evaluate quality of life.  
Conclusions 
Quality of life is of paramount importance when treating cats for lymphoma.  The quality of 
life scores observed with this doxorubicin-containing protocol were not worse than a 
previous study using cyclophosphamide, vincristine and prednisolone, employing the same 
scoring system.  Although quality of life scores during chemotherapy were not significantly 
improved over those at diagnosis, the protocol was well tolerated and owner satisfaction 
with the protocol was high. Since appetite during chemotherapy was positively associated 
with the owner’s perception of their cat’s QOL during chemotherapy, appetite should be 
proactively monitored and reasons for poor appetite addressed.  Factors contributing to 
quality of life are multifactorial and complex.  Further work is needed to determine what 
parameters owners truly use to assess the quality of life of their cats.    
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Figure 1. Box and whisker plot illustrating the quality of life scores (1–10) given by the 
owners of 20 cats with lymphoma at three time points: before lymphoma was diagnosed 
(‘before diagnosis’), at diagnosis (‘at diagnosis’) and during a modified University of 
Wisconsin–Madison chemotherapy protocol (‘during chemotherapy’) 
 
 
 
 
 
 
 
 
Figure 2. Owner (n = 20) assignment of the importance of various different health-related 
parameters when evaluating their cat’s quality of life. Percentage of owners and their 
ratings of importance are represented on the x-axis and the health-related parameters are 
represented on the y-axis 
 
 
 
  
Table 1. Spearman’s rank correlation showing the correlation of variables and quality of life 
scores in 20 cats diagnosed with lymphoma at 3 time points: before diagnosis, at diagnosis 
and during chemotherapy 
 
Stage of disease 
Correlation 
coefficient 
(Rho) P value 
Before diagnosis 
Appetite 0.1671 0.4814 
Body weight 0.3517 0.1283 
General activity 0.2739 0.2426 
Playfulness 0.1407 0.554 
Sleeping 0.4136 0.0699 
Grooming 0.2486 0.2907 
Vomiting -0.1108 0.642 
Diarrhoea -0.3122 0.1803 
Diagnosis 
Appetite 0.2794 0.2328 
Body weight 0.6398 0.0024 
General activity 0.6432 0.0022 
Playfulness 0.7141 0.0004 
Sleeping -0.0544 0.8198 
Grooming 0.693 0.0007 
Vomiting 0.337 0.1462 
Diarrhoea 0.1879 0.4275 
During chemotherapy 
Appetite 0.5243 0.0176 
Body weight 0.3087 0.1854 
General activity 0.3667 0.1117 
Playfulness 0.4386 0.0531 
Sleeping 0.0783 0.7427 
Grooming -0.041 0.8638 
Vomiting 0.0012 0.9961 
Diarrhoea 0.2374 0.3135 
Significant values are given in bold 
